Alan Frazer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7911490/publications.pdf

Version: 2024-02-01

138 papers	6,894 citations	66234 42 h-index	64668 79 g-index
151 all docs	151 docs citations	151 times ranked	6044 citing authors

#	Article	IF	Citations
1	Hippocampal Î±5-GABAA Receptors Modulate Dopamine Neuron Activity in the Rat Ventral Tegmental Area. Biological Psychiatry Global Open Science, 2023, 3, 78-86.	1.0	8
2	Antidepressant Drugs. , 2021, , .		0
3	IN MEMORIAM-Stephen Hugh Koslow, Ph.D. International Journal of Neuropsychopharmacology, 2021, 24, 449-449.	1.0	0
4	In memoriamâ€"Stephen Hugh Koslow, Ph.D. Neuropsychopharmacology, 2021, 46, 1702-1702.	2.8	0
5	Mechanisms associated with the antidepressant-like effects of L-655,708. Neuropsychopharmacology, 2020, 45, 2289-2298.	2.8	9
6	Ketamine: Leading us into the future for development of antidepressants. Behavioural Brain Research, 2020, 383, 112532.	1.2	12
7	Editorial for Treatment-Resistant Depression (TRD). International Journal of Neuropsychopharmacology, 2019, 22, 83-84.	1.0	8
8	Vagal Nerve Stimulation for Treatment-Resistant Depression. Neurotherapeutics, 2017, 14, 716-727.	2.1	136
9	Selective Pharmacological Augmentation of Hippocampal Activity Produces a Sustained Antidepressant-Like Response without Abuse-Related or Psychotomimetic Effects. International Journal of Neuropsychopharmacology, 2017, 20, 504-509.	1.0	25
10	Comparison of the Antidepressant-Like Effects of Estradiol and That of Selective Serotonin Reuptake Inhibitors in Middle-Aged Ovariectomized Rats. Frontiers in Aging Neuroscience, 2016, 8, 311.	1.7	15
11	A Neuroscience-Based Nomenclature (NbN) for Psychotropic Agents. International Journal of Neuropsychopharmacology, 2016, 19, pyw066.	1.0	13
12	The Allure of Transcutaneous Vagus Nerve Stimulation as a Novel Therapeutic Modality. Biological Psychiatry, 2016, 79, 260-261.	0.7	22
13	Activation of a ventral hippocampusâ€"medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine. Molecular Psychiatry, 2016, 21, 1298-1308.	4.1	170
14	Effects of Long-Term Treatment with Estradiol and Estrogen Receptor Subtype Agonists on Serotonergic Function in Ovariectomized Rats. Neuroendocrinology, 2016, 103, 269-281.	1.2	31
15	Evidence for Shortening the Duration of Clinical Trials of Antidepressants and a Proposed Paradigm for Such Studies. Journal of Clinical Psychopharmacology, 2015, 35, 329-332.	0.7	0
16	Neuropsychopharmacology: Reflections on 40 Volumes. Neuropsychopharmacology, 2015, 40, 2853-2855.	2.8	1
17	Vagal Nerve Stimulation Reverses Aberrant Dopamine System Function in the Methylazoxymethanol Acetate Rodent Model of Schizophrenia. Journal of Neuroscience, 2014, 34, 9261-9267.	1.7	49
18	Signaling mechanisms involved in the acute effects of estradiol on 5-HT clearance. International Journal of Neuropsychopharmacology, 2014, 17, 765-777.	1.0	33

#	Article	IF	Citations
19	Activation of signaling pathways downstream of the brain-derived neurotrophic factor receptor, TrkB, in the rat brain by vagal nerve stimulation and antidepressant drugs. International Journal of Neuropsychopharmacology, 2014, 17, 247-258.	1.0	19
20	Influence of acute or chronic administration of ovarian hormones on the effects of desipramine in the forced swim test in female rats. Psychopharmacology, 2014, 231, 3685-3694.	1.5	10
21	Therapeutic Modalities for Treatment Resistant Depression: Focus on Vagal Nerve Stimulation and Ketamine. Clinical Psychopharmacology and Neuroscience, 2014, 12, 83-93.	0.9	29
22	Exogenous prenatal corticosterone exposure mimics the effects of prenatal stress on adult brain stress response systems and fear extinction behavior. Psychoneuroendocrinology, 2013, 38, 2746-2757.	1.3	58
23	Preclinical models of schizophrenia. International Journal of Neuropsychopharmacology, 2013, 16, 2129-2129.	1.0	0
24	Comparison of Î”FosB Immunoreactivity Induced by Vagal Nerve Stimulation with That Caused by Pharmacologically Diverse Antidepressants. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 317-325.	1.3	23
25	Comparison of the Effects of Estradiol and Progesterone on Serotonergic Function. Biological Psychiatry, 2012, 71, 633-641.	0.7	55
26	Effects of chronic plus acute prolonged stress on measures of coping style, anxiety, and evoked HPA-axis reactivity. Neuropharmacology, 2012, 63, 1118-1126.	2.0	64
27	Vagal Nerve Stimulation Rapidly Activates Brain-Derived Neurotrophic Factor Receptor TrkB in Rat Brain. PLoS ONE, 2012, 7, e34844.	1.1	71
28	Serotonergic and Noradrenergic Pathways Are Required for the Anxiolytic-like and Antidepressant-like Behavioral Effects of Repeated Vagal Nerve Stimulation in Rats. Biological Psychiatry, 2011, 70, 937-945.	0.7	92
29	Prenatal stress induces long term stress vulnerability, compromising stress response systems in the brain and impairing extinction of conditioned fear after adult stress. Neuroscience, 2011, 192, 438-451.	1.1	112
30	Corticosterone and prolactin response to TFMPP in rats during repeated antidepressant administration. Journal of Pharmacy and Pharmacology, 2011, 43, 54-56.	1.2	5
31	The Componential Approach Enhances the Effectiveness of 2-Week Trials for New Antidepressants. Journal of Clinical Psychopharmacology, 2011, 31, 253-254.	0.7	2
32	Rethinking depression and the actions of antidepressants: Uncovering the links between the neural and behavioral elements. Journal of Affective Disorders, 2010, 120, 16-23.	2.0	34
33	Impact of Ovarian Hormones on the Modulation of the Serotonin Transporter by Fluvoxamine. Neuropsychopharmacology, 2009, 34, 555-564.	2.8	37
34	Influence of brain-derived neurotrophic factor (BDNF) on serotonin neurotransmission in the hippocampus of adult rodents. European Journal of Pharmacology, 2008, 587, 90-98.	1.7	47
35	Chronic Unpredictable Stress Induces a Cognitive Deficit and Anxiety-Like Behavior in Rats that is Prevented by Chronic Antidepressant Drug Treatment. Neuropsychopharmacology, 2008, 33, 320-331.	2.8	332
36	Induction of c-Fos and Î”FosB Immunoreactivity in Rat Brain by Vagal Nerve Stimulation. Neuropsychopharmacology, 2008, 33, 1884-1895.	2.8	143

#	Article	IF	Citations
37	Effect of Chronic Administration of Duloxetine on Serotonin and Norepinephrine Transporter Binding Sites in Rat Brain. Biological Psychiatry, 2007, 61, 210-215.	0.7	12
38	The norepinephrine transporter and regulation of synaptic transmission. , 2007, , 119-154.		0
39	Neuropathology of central norepinephrine in psychiatric disorders: postmortem research. , 2007, , 341-362.		7
40	CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. Journal of Neurochemistry, 2007, 101, 389-396.	2.1	41
41	[3H] Citalopram Binding to Serotonin Transporter Sites in Minnow Brains. Basic and Clinical Pharmacology and Toxicology, 2007, 101, 203-210.	1.2	42
42	A Comparison of the Chronic Treatment Effects of Venlafaxine and Other Antidepressants on Serotonin and Norepinephrine Transporters. Biological Psychiatry, 2006, 59, 408-414.	0.7	48
43	A video method for the evaluation of antidepressant clinical and behavioural actions. International Journal of Neuropsychopharmacology, 2006, 9, 327.	1.0	4
44	Resolving the Onset of Antidepressants' Clinical Actions. Journal of Clinical Psychopharmacology, 2006, 26, 549-553.	0.7	11
45	Leptin: A potential novel antidepressant. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1593-1598.	3.3	380
46	VNS Therapy in Treatment-Resistant Depression: Clinical Evidence and Putative Neurobiological Mechanisms. Neuropsychopharmacology, 2006, 31, 1345-1355.	2.8	367
47	Transport mechanisms governing serotonin clearance in vivo revealed by high-speed chronoamperometry. Journal of Neuroscience Methods, 2005, 143, 49-62.	1.3	77
48	What should animal models of depression model?. Neuroscience and Biobehavioral Reviews, 2005, 29, 515-523.	2.9	117
49	Onset and Early Behavioral Effects of Pharmacologically Different Antidepressants and Placebo in Depression. Neuropsychopharmacology, 2004, 29, 566-579.	2.8	252
50	Serotonin (5-HT) transporter (SERT) function after graded destruction of serotonergic neurons. Journal of Neurochemistry, 2004, 87, 861-867.	2.1	26
51	Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. International Journal of Neuropsychopharmacology, 2004, 7, 193-218.	1.0	213
52	Mechanisms of antidepressant action: is onset early or late?. Drug Discovery Today Disease Mechanisms, 2004, 1, 429-433.	0.8	0
53	Regulation of the norepinephrine transporter by chronic administration of antidepressants. Biological Psychiatry, 2004, 55, 313-316.	0.7	64
54	A multivantaged behavioural method for measuring onset and sequence of the clinical actions of antidepressants. International Journal of Neuropsychopharmacology, 2004, 7, 471-479.	1.0	18

#	Article	IF	Citations
55	Quantitative autoradiographic analysis of the new radioligand [3H](2E)-(5-hydroxy-5,7,8,9-tetrahydro-6H-benzo[a][7]annulen-6-ylidene) ethanoic acid ([3H]NCS-382) at [3-hydroxybutyric acid (GHB) binding sites in rat brain. Brain Research, 2003, 979, 51-56.	1.1	33
56	Selective Decreases in Amphetamine Self-Administration and Regulation of Dopamine Transporter Function in Diabetic Rats. Neuroendocrinology, 2003, 77, 132-140.	1.2	43
57	Regulatory Effects of Reboxetine Treatment Alone, or Following Paroxetine Treatment, on Brain Noradrenergic and Serotonergic Systems. Neuropsychopharmacology, 2003, 28, 1633-1641.	2.8	31
58	New Developments in the Regulation of Monoaminergic Neurotransmission. , 2003, , 25-42.		0
59	Serotonin ClearanceIn VivoIs Altered to a Greater Extent by Antidepressant-Induced Downregulation of the Serotonin Transporter than by Acute Blockade of this Transporter. Journal of Neuroscience, 2002, 22, 6766-6772.	1.7	166
60	Differential in vivo clearance of serotonin in rat dorsal raphe nucleus and CA3 region. Brain Research, 2002, 955, 236-244.	1.1	20
61	Enhancing the Technology of Clinical Trials and the Trials Model to Evaluate Newly Developed, Targeted Antidepressants. Neuropsychopharmacology, 2002, 27, 319-328.	2.8	22
62	5-HT1B Receptor-Mediated Regulation of Serotonin Clearance in Rat Hippocampus In Vivo. Journal of Neurochemistry, 2002, 75, 2113-2122.	2.1	71
63	Characterization of 5-HT1A,Band 5-HT2A,CSerotonin Receptor Binding. , 2001, Chapter 1, Unit1.23.		4
64	Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. International Journal of Neuropsychopharmacology, 2000, 3, 229-235.	1.0	65
65	New views of biogenic amine transporter function: implications for neuropsychopharmacology. International Journal of Neuropsychopharmacology, 1999, 2, 305-320.	1.0	23
66	Effects of Chronic Antidepressant Treatments on Serotonin Transporter Function, Density, and mRNA Level. Journal of Neuroscience, 1999, 19, 10494-10501.	1.7	283
67	5-HT1B antagonists modulate clearance of extracellular serotonin in rat hippocampus. Neuroscience Letters, 1999, 266, 165-168.	1.0	33
68	Serotonin Transporter Function in vivo: Assessment by Chronoamperometrya. Annals of the New York Academy of Sciences, 1998, 861, 217-229.	1.8	15
69	The International Journal of Neuropsychopharmacology. International Journal of Neuropsychopharmacology, 1998, 1, 1-2.	1.0	3
70	Effects of antidepressant treatment on inhibitory avoidance behavior and amygdaloid beta-adrenoceptors in rats. Neuropsychopharmacology, 1998, 19, 300-13.	2.8	7
71	Venlafaxine:a novel antidepressant compound. Expert Opinion on Investigational Drugs, 1997, 6, 65-78.	1.9	28
72	Correspondence. Neuropsychopharmacology, 1997, 17, 110-112.	2.8	26

#	Article	IF	Citations
73	In vivo chronoamperometric measurements of the clearance of exogenously applied serotonin in the rat dentate gyrus. Journal of Neuroscience Methods, 1997, 78, 139-150.	1.3	38
74	Pharmacology of Antidepressants. Journal of Clinical Psychopharmacology, 1997, 17, 2S-18S.	0.7	208
75	Onset of antidepressant activity: Reexamining the structure of depression and multiple actions of drugs. Depression and Anxiety, 1996, 4, 257-267.	2.0	60
76	Effects of novel 5-HT1A receptor antagonists on measures of postsynaptic 5-HT1A receptor activation in vivo. Life Sciences, 1995, 56, PL163-PL168.	2.0	41
77	Drug-Induced Actions on Brain Neurotransmitter Systems and Changes in the Behaviors and Emotions of Depressed Patients. Neuropsychopharmacology, 1994, 11, 89-100.	2.8	40
78	Quantitative autoradiography of the serotonin transporter to assess the distribution of serotonergic projections from the dorsal raphe nucleus. Synapse, 1994, 17, 1-15.	0.6	91
79	Antidepressant drugs. Depression, 1994, 2, 1-19.	0.7	18
80	Effect of Chronic Administration of Antidepressants on Î±2-Adrenoceptors in the Locus Coeruleus and Its Projection Fields in Rat Brain Determined by Quantitative Autoradiography. Neuropsychopharmacology, 1993, 8, 57-65.	2.8	42
81	Iodinated tomoxetine derivatives as selective ligands for serotonin and norepinephrine uptake sites. Journal of Medicinal Chemistry, 1992, 35, 4492-4497.	2.9	39
82	Central administration of 1-isoproterenol in vivo induces a preferential regulation of Î²2-adrenoceptors in the central nervous system of the rat. Brain Research, 1991, 555, 141-148.	1.1	15
83	Identifying the specific clinical actions of amitriptyline: interrelationships of behaviour, affect and plasma levels in depression. Psychological Medicine, 1991, 21, 599-611.	2.7	41
84	Subtypes of Receptors for Serotonin. Annual Review of Pharmacology and Toxicology, 1990, 30, 307-348.	4.2	202
85	5-HT1AReceptors and 5-HT1A-Mediated Responses: Effect of Treatments That Modify Serotonergic Neurotransmission. Annals of the New York Academy of Sciences, 1990, 600, 460-474.	1.8	53
86	Lithium distribution in mania: Single-dose pharmacokinetics and sympathoadrenal function. Psychiatry Research, 1990, 32, 71-84.	1.7	14
87	[3H]Nisoxetine: a new radioligand for norepinephrine uptake sites in brain. European Journal of Pharmacology, 1990, 191, 239-243.	1.7	94
88	Factors Contributing to Erythrocyte Lithium-Sodium Countertransport Activity in Lithium-Treated Bipolar Patients. Pharmacopsychiatry, 1989, 22, 16-20.	1.7	7
89	Pituitary-adrenal and thyroid effects on melatonin content of the rat pineal gland. Psychoneuroendocrinology, 1989, 14, 165-175.	1.3	10
90	Evaluation of mono- and dibenzoyl esters of dopamine as potential pro-drugs for dopamine in the central nervous system. Naunyn-Schmiedeberg's Archives of Pharmacology, 1988, 338, 497-503.	1.4	2

#	Article	IF	Citations
91	Quantitative autoradiography of serotonin uptake sites in rat brain using [3H]cyanoimipramine. Brain Research, 1988, 454, 78-88.	1.1	95
92	Effects of prenalterol on beta adrenergic responsiveness and receptors in the cerebral cortex of the rat. Neuropharmacology, 1988, 27, 529-536.	2.0	1
93	Kinetics of erythrocyte lithiumâ€"sodium countertransport in patients with affective illness before and during lithium therapy. Journal of Affective Disorders, 1988, 14, 75-81.	2.0	8
94	Insulin-induced hypoglycaemic response and release of growth hormone in depressed patients and healthy controls. Psychological Medicine, 1988, 18, 79-91.	2.7	8
95	Regulation of Serotonin Receptors and Responsiveness in the Brain. , 1988, , 319-362.		24
96	The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychological Medicine, 1987, 17, 297-309.	2.7	164
97	Depressed mood and reality disturbance correlate with decreased nocturnal melatonin in depressed patients. Acta Psychiatrica Scandinavica, 1987, 76, 272-275.	2.2	53
98	Lithium distribution in mania: Plasma and red blood cell lithium, clinical state, and monoamine metabolites during lithium treatment. Psychiatry Research, 1987, 20, 1-12.	1.7	9
99	Effect of Repeated Administration of Clenbuterol on the Regulation of Î²â€Adrenoceptors in the Central Nervous System of the Rat. Novartis Foundation Symposium, 1986, 123, 170-190.	1.2	7
100	Performance and extinction of lever press behavior following chronic administration of desipramine to rats. Psychopharmacology, 1985, 85, 253-259.	1.5	12
101	Development of selective tolerance to the serotonin behavioral syndrome and suppression of locomotor activity after repeated administration of either 5-MeODMT or mCPP. Life Sciences, 1985, 36, 2463-2469.	2.0	49
102	Cerebrospinal fluid levels of amitriptyline, nortriptyline, imipramine and desmethylimipramine. Journal of Affective Disorders, 1985, 9, 69-78.	2.0	11
103	ALTERATIONS IN MONOAMINEâ€CONTAINING NEURONAL FUNCTION DUE TO ADMINISTRATION OF ANTIDEPRESSANTS REPEATEDLY TO RATS.. Acta Pharmacologica Et Toxicologica, 1985, 56, 21-34.	0.0	10
104	Pharmacologic Mechanisms of Action of Antidepressants. Psychiatric Clinics of North America, 1984, 7, 575-586.	0.7	25
105	Amish study, V: Lithium-sodium countertransport and catechol O- methyltransferase in pedigrees of bipolar probands. American Journal of Psychiatry, 1984, 141, 1049-1054.	4.0	16
106	The effect of antidepressant drugs on regional cerebral glucose utilization in the rat. Brain Research, 1983, 269, 319-325.	1.1	37
107	Continuous light paradoxically reduces catecholamine-induced melatonin production. Brain Research, 1983, 267, 175-178.	1.1	2
108	Plasma and erythrocyte electrolytes in affective disorders. Journal of Affective Disorders, 1983, 5, 103-113.	2.0	38

#	Article	IF	Citations
109	Is theâ€œnewâ€•more useful than theâ€œoldâ€?. Behavioral and Brain Sciences, 1983, 6, 554.	0.4	0
110	Prevention of the serotonin syndrome in rats by repeated administration of monoamine oxidase inhibitors but not tricyclic antidepressants. Psychopharmacology, 1982, 77, 205-211.	1.5	91
111	Electrical stimulation of sympathetic nerves increases the concentration of cyclic AMP in rat pineal gland.. Proceedings of the National Academy of Sciences of the United States of America, 1981, 78, 7176-7179.	3.3	26
112	A pilot study of racial differences in erythrocyte lithium transport. American Journal of Psychiatry, 1980, 137, 120-121.	4.0	21
113	Do tricyclic antidepressants enhance adrenergic transmission? An update. American Journal of Psychiatry, 1980, 137, 113-114.	4.0	17
114	Inhibitory Effects of Desmethylimipramine on the Action of Thyroxine on Cardiac Beta-Receptors and Myocardial Phosphorylase. Journal of Cardiovascular Pharmacology, 1980, 2, 867-880.	0.8	2
115	The effect of psychoactive drugs on beta-adrenergic receptor binding sites in rat brain. Neuropharmacology, 1980, 19, 447-454.	2.0	196
116	Decrease in [3H]-serotonin binding in rat brain produced by the repeated administration of either monoamine oxidase inhibitors or centrally acting serotonin agonists. Neuropharmacology, 1980, 19, 1063-1070.	2.0	54
117	Effects of darkness and of desmethylimipramine on pineal gland concentrations of adenosine 3', 5'-monophosphate. Biochemical Pharmacology, 1980, 29, 1341-1346.	2.0	11
118	The lithium ratio as a guide to patient compliance. Comprehensive Psychiatry, 1980, 21, 276-280.	1.5	14
119	A Study of Growth Hormone Release in Depression. Neuropsychobiology, 1979, 5, 282-289.	0.9	36
120	Plasma and Erythrocyte Cations in Affective Illness. Neuropsychobiology, 1979, 5, 1-10.	0.9	12
121	Differential effects of monoamine oxidase inhibitors and serotonin reuptake inhibitors on 3H-serotonin receptor binding in rat brain. European Journal of Pharmacology, 1979, 58, 87-88.	1.7	46
122	Opposite effects of acute and repeated administration of desmethylimipramine on adrenergic responsiveness in rat pineal gland. Life Sciences, 1979, 24, 2237-2244.	2.0	38
123	Lithium ion uptake associated with the stimulation of action potential ionophores of cultured human neuroblastoma cells. Life Sciences, 1979, 25, 957-967.	2.0	11
124	Transfer of sodium ions across the erythrocyte membrane in manic â€" Depressive illness: Treatment with lithium carbonate. Life Sciences, 1978, 22, 157-164.	2.0	9
125	Desmethylimipramine-induced decrease in Î²-adrenergic receptor binding in rat cerebral cortex. Biochemical Pharmacology, 1978, 27, 2179-2181.	2.0	137
126	Red Blood Cell Li⁺ to Plasma Li⁺ Ratios. Neuropsychobiology, 1978, 4, 121-127.	0.9	9

#	Article	IF	Citations
127	Prediction of the lithium ratio in man by means of an in vitro test. Clinical Pharmacology and Therapeutics, 1977, 22, 465-469.	2.3	17
128	LITHIUM RATIO AND CLINICAL RESPONSE IN MANIC-DEPRESSIVE ILLNESS. Lancet, The, 1977, 309, 41-42.	6.3	23
129	Distribution of the lithium ion in endocrine organs of the rat. Life Sciences, 1977, 20, 1669-1674.	2.0	12
130	Intracellular Lithium and Clinical Response. British Journal of Psychiatry, 1976, 128, 103-104.	1.7	25
131	Reduced Central Serotonergic Activity in Mania: Implications for the Relationship between Depression and Mania. British Journal of Psychiatry, 1975, 126, 241-248.	1.7	32
132	Apomorphine: Effect on Growth Hormone. Journal of Clinical Endocrinology and Metabolism, 1975, 40, 162-163.	1.8	45
133	Metabolic and electrolyte changes produced by lithium ions in the isolated rat diaphragm. Biochemical Pharmacology, 1975, 24, 1187-1191.	2.0	17
134	Effects of intracellular lithium on epinephrine-induced accumulation of cyclic AMP in skeletal muscle. Biochemical Pharmacology, 1975, 24, 2273-2277.	2.0	18
135	Platelet adenylate cyclase responses in depression: Implications for a receptor defect. Psychopharmacology, 1974, 36, 291-300.	1.5	53
136	Effect of lithium on prostaglandin E1â" stimulated adenylate cyclase activity of human platelets. Biochemical Pharmacology, 1974, 23, 845-855.	2.0	49
137	A method for the determination of sodium, potassium, magnesium and lithium concentrations in erythrocytes. Clinica Chimica Acta, 1972, 36, 499-509.	0.5	57
138	The effect of lithium carbonate on self-stimulating behavior in the rat. Life Sciences, 1972, 11, 773-779.	2.0	13